Skip to main content
. Author manuscript; available in PMC: 2017 Oct 18.
Published in final edited form as: Pediatr Res. 2010 Sep;68(3):248–251. doi: 10.1203/PDR.0b013e3181eb2f18

Figure 1.

Figure 1

Plasma levels of IL-6 and IL-8 in preterm infants receiving TPN. Preterm infants were allocated to receive one of the following TPN regimens: AA, multivitamin (MVP) +amino acid/dextrose solution with lipid (LIP) provided separately (n = 9); LE, MVP administered with LIP exposed to light with amino acid/dextrose solutions provided separately (n = 9); LP, MVP administered with LIP protected from light with amino acid/dextrose solutions provided separately (n = 8). IL-6 (left panel) and IL-8 (right panel) were measured from plasma sampled on 7th day of life (● sample 1) and 10th day of life (○ sample 2). Data (mean ±SD) were compared by ANOVA between infants (n = sample 1; sample 2) exposed to low (<0.25) vs high (≥ 0.25) FiO2; *p < 0.05.